Related Experiment Video

Updated: Aug 7, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Novel gene-directed enzyme prodrug therapies against prostate cancer

Pamela J Russell1, Aparajita Khatri

  • 1Oncology Research Centre, Prince of Wales Hospital Sydney, Level 2, Clinical Sciences Building, Barker Street, Randwick, NSW 2031, Australia. p.Russell@unsw.edu.au

Expert Opinion on Investigational Drugs
|July 25, 2006
PubMed

Insights

Gene-directed enzyme prodrug therapy (GDEPT) offers a promising alternative to chemotherapy for advanced prostate cancer. This review explores GDEPT

Area of Science:

  • Oncology
  • Gene Therapy
  • Prostate Cancer Research

Background:

  • Late-stage hormone-refractory prostate cancer lacks effective curative treatments.
  • Current chemotherapy provides palliation but causes significant systemic toxicities and reduces quality of life.
  • Novel therapeutic strategies are crucial for improving outcomes in advanced prostate cancer.

Purpose of the Study:

  • To review the development, application, and potential of gene-directed enzyme prodrug therapy (GDEPT) for prostate cancer.
  • To assess current research on enhancing in situ GDEPT delivery and vector targeting in prostate cancer.
  • To discuss the synergistic potential of GDEPT with other treatment modalities.

Main Methods:

  • Literature review focusing on GDEPT strategies for prostate cancer.
  • Assessment of in vivo gene delivery methods and vector targeting for GDEPT.
  • Analysis of combined treatment approaches involving GDEPT.

Main Results:

  • GDEPT shows potential for localized tumor cell killing with bystander effects, advantageous for prostate cancer.
  • Enhancing in situ GDEPT delivery and prostate cancer-specific vector targeting remain key research areas.
  • Synergies between GDEPT and traditional/alternate therapies are being explored to improve efficacy.

Conclusions:

  • GDEPT represents a biologically relevant alternative to chemotherapy for advanced prostate cancer.
  • Further research into optimized delivery and targeting is essential for clinical translation of GDEPT.
  • Combination strategies hold promise for maximizing therapeutic benefits in prostate cancer treatment.

More Related Videos

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...